Skip to main content

Korro Bio, Inc.

KRRO
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001703647

In the last 90 days, Korro Bio, Inc. insiders filed 1 open-market purchase and 8 sales; 106 institutions reported holding it in 13F filings for Q2 2026, worth $190.1M in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Korro Bio, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
1 filing
1 insider, $78.8K in total
Open-market sells
8 filings
3 insiders, $2.82M in total
Insiders trading
4
Net value
−$2.75M
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Korro Bio, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Korro Bio, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Formela Jean FrancoisDirector132,650IndirectSep 15, 20268
Dolan OliverSenior Vice President, Finance16,241Sep 14, 20266
Nichols Weston10% Owner1,544,980IndirectAug 13, 20262
Lynx1 Capital Management LP10% Owner1,544,980IndirectAug 13, 20262
Aiyar RamPresident and CEO69,046Aug 5, 20264
Vincent Loic AChief Scientific Officer25,797Jul 17, 20264
Cerio JeffreyGeneral Counsel41,793Jul 17, 20264
Chappell ToddChief Operating Officer24,464Jul 17, 20264
Bermingham NessanDirector35,114Jun 11, 20261
Pearson Timothy RDirector–Jun 11, 20261
Behbahani AliDirector1,297,893IndirectJun 11, 20262
Knobil KatharineDirector–Jun 11, 20261
Meyers RachelDirector–Jun 11, 20261
New Enterprise Associates 17, L.P.10% Owner1,297,893Mar 12, 20261
NEA Partners 17, L.P.10% Owner1,297,893Mar 12, 20261
Nea 17 GP, LLC10% Owner1,297,893Mar 12, 20261
Sandell Scott D10% Owner1,297,893IndirectMar 12, 20261
Baskett Forest10% Owner1,297,893IndirectMar 12, 20261
Mathers Edward T10% Owner1,297,893IndirectMar 12, 20261
Walker Paul Edward10% Owner1,297,893IndirectMar 12, 20261
Florence Anthony A. Jr.10% Owner1,297,893IndirectMar 12, 20261
Makhzoumi Mohamad10% Owner1,297,893IndirectMar 12, 20261
Chang Carmen10% Owner1,297,893IndirectMar 12, 20261
Yang Rick10% Owner1,297,893IndirectMar 12, 20261
Agarwal VineetChief Financial Officer0Feb 5, 20250
Olugemo OlukemiChief Medical Officer–Feb 5, 20250
Lucchino David L.Director22,150Jun 12, 20240
Atlas Venture Opportunity Fund II, L.P.10% Owner195,074Apr 23, 20240
Atlas Venture Associates Opportunity II, LLC10% Owner195,074Apr 23, 20240
Atlas Venture Associates Opportunity II, LP10% Owner195,074Apr 23, 20240
Colletti SteveChief Scientific Officer–Nov 7, 20230
Walker Shelby J.See Remarks–Nov 7, 20230
Mitrano Richard J.VP Finance & Operations48,457Aug 22, 20230
Loose Christopher R.Chief Scientific Officer183,650Jul 31, 20230
LeBel CarlChief Development Officer26,343Jan 27, 20230
Arnold Wendy SChief People Officer21,186Jan 27, 20230
McCubbin QuentinChief Manufacturing Officer38,340Jan 27, 20230
Barberich Timothy JDirector–Aug 19, 20220
Marcus Joel SDirector–Aug 19, 20220
Langer RobertDirector–Aug 19, 20220
Feldmann Cynthia LDirector–Aug 19, 20220
Huang MichaelDirector–Aug 19, 20220
Cohen Marc ADirector–Jun 23, 20220
Pfreundschuh Peter P.Chief Financial Officer8,927Feb 23, 20220

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Feb 23, 2022 (view filing)Feb 18-225 daysMcCubbin QuentinChief Manufacturing OfficerSSale−3.00K$3.69−$11.1K−11.6%22.8K after2 lots
Feb 23, 2022 (view filing)Feb 18-225 daysArnold Wendy SChief People OfficerSSale−2.54K$3.69−$9.36K−17.7%11.8K after2 lots
Feb 18, 2022 (view filing)Feb 16-172 daysPfreundschuh Peter P.Chief Financial OfficerSSale−2.52K$4.31−$10.9K−17.5%11.9K after2 lots
Feb 18, 2022 (view filing)Feb 16-172 daysLoose Christopher R.Chief Scientific OfficerSSale−1.75K$4.31−$7.54K−4.5%36.9K after2 lots
Feb 18, 2022 (view filing)Feb 16-172 daysLeBel CarlChief Development OfficerSSale−1.73K$4.31−$7.46K−11.6%13.2K after2 lots
Feb 18, 2022 (view filing)Feb 16-172 daysMcCubbin QuentinChief Manufacturing OfficerSSale−2.54K$4.31−$10.9K−9.0%25.8K after2 lots
Feb 18, 2022 (view filing)Feb 16-172 daysArnold Wendy SChief People OfficerSSale−2.17K$4.31−$9.37K−13.2%14.4K after2 lots
Feb 16, 2022 (view filing)Feb 151 dayLeBel CarlChief Development OfficerSSale−844$4.33−$3.65K−5.4%14.9K after
Feb 16, 2022 (view filing)Feb 151 dayMcCubbin QuentinChief Manufacturing OfficerSSale−1.26K$4.33−$5.46K−4.3%28.3K after
Feb 16, 2022 (view filing)Feb 151 dayLoose Christopher R.Chief Scientific OfficerSSale−863$4.33−$3.74K−2.2%38.6K after
Feb 16, 2022 (view filing)Feb 151 dayPfreundschuh Peter P.Chief Financial OfficerSSale−1.35K$4.33−$5.83K−8.6%14.4K after
Feb 16, 2022 (view filing)Feb 151 dayArnold Wendy SChief People OfficerSSale−1.17K$4.33−$5.06K−6.6%16.5K after